Drugs / TELISOTUZUMAB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01472016 | Oct 2011 → Apr 2017 | — | AbbVie | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TELISOTUZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545419 ↗ |
| Known as | ABT-700 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01472016 ↗ |
| Known as | h224G11 | “ABT-700, previously known as h224G11 in publications, is an anti-c-Met antibody.” NCT01472016 ↗ |
| Modality | Monoclonal antibody | “ABT-700, a Monoclonal Antibody” NCT01472016 ↗ |
| Route | Intravenous | “ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles.” NCT01472016 ↗ |
| Target | MET | “ABT-700, previously known as h224G11 in publications, is an anti-c-Met antibody.” NCT01472016 ↗ |